June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that adults aged 60 and above may receive the recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections. (Reporting by Raghav Mahobe in Bengaluru and Michael Erman in New York; Editing by Leslie Adler)
Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses
FTSE 100 down 0.2%, FTSE 250 up 0.8%
*Read more